Merck Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS
DARMSTADT, Germany -- (BUSINESS WIRE) -- Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced updated long-term efficacy and safety da......